Last updated: February 13, 2026
What Is the Current Market Status for NDC 72578-0063?
The drug identified by NDC 72578-0063 is Vyleesi (bremelanotide). It is indicated as a on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. It was approved by the FDA in June 2019.
Vyleesi has gained market entry with limited direct competition, as it is one of the few pharmacologic options specifically approved for female HSDD. Its market status remains dominated by niche positioning, with sales volume reflecting its targeted use case.
Sales data from IQVIA suggest first-year revenues approximately $25 million. Growth has been slow due to factors like limited awareness, insurance reimbursement hurdles, and the rarity of the condition.
How Is the Market Landscape Evolving?
Key Competitors and Alternatives
- No direct competitors are currently approved for HSDD, although off-label use of medications like flibanserin (Addyi) occurs.
- Flibanserin, approved for similar premenopausal women with hypoactive desire, entered the market earlier (2015). It had first-year sales around $28 million and faced regulatory and market penetration challenges.
- Future competition could arise from novel pharmacological agents, including non-oral formulations or drugs targeting underlying causes.
Regulatory and Reimbursement Trends
- Reimbursement landscape remains cautious. Commercial insurers are slow to adopt coverage, limiting patient access.
- The drug’s labeling specifies on-demand administration, aligning with patient preferences but constraining potential sales volume.
Pricing Strategy
- The wholesale acquisition cost (WAC) is approximately $850 per dose.
- Estimated out-of-pocket costs for patients range from $150 to $300 per administration, depending on insurance coverage.
- The drug’s cost-effectiveness is under review, considering its limited patient population and modest sales.
Price Projections and Market Potential
Short-Term Outlook (Next 1-2 Years)
- Sales are projected to stabilize near current levels ($25-$30 million annually), barring aggressive marketing or formulary inclusion.
- Price per dose is unlikely to change significantly in the short term.
Medium to Long-Term Outlook (3-5 Years)
- Market adoption could increase marginally due to physician education initiatives and expanded insurance coverage.
- An increase in prescriptions could raise FY 2025 revenues to approximately $50 million if coverage improves and awareness spreads.
- Price per dose may remain steady or increase slightly (up to $900) in response to inflation, continued regulatory approval, or market exclusivity benefits.
Drivers of Price and Market Growth
- Expansion into new territories.
- Broader insurance coverage and reduced patient out-of-pocket costs.
- Potential uptake of alternative, more convenient formulations.
Risks to Price and Market Growth
- Competition from future agents or generic equivalents.
- Reimbursement restrictions.
- Limited patient pool due to the specific diagnosis criteria.
Key Considerations for Stakeholders
- Pharma companies should evaluate strategic partnerships to improve market penetration.
- Investors should monitor regulatory developments that could expand or restrict access.
- Payers need to assess cost-effectiveness to inform reimbursement decisions.
Summary Table: Price and Market Data for NDC 72578-0063
| Parameter |
Data/Estimate |
| Current wholesale price per dose |
~$850 |
| Estimated annual sales (2022) |
~$25 million |
| First-year sales (2019) |
~$25 million |
| Projected sales (2025) |
Up to $50 million if market expands |
| Reimbursement coverage rate |
~40-50% (varies by insurer) |
| Patient out-of-pocket cost per dose |
$150-$300 |
Conclusions
Vyleesi continues to hold a small but steady niche within hormonal and female sexual health markets. Its pricing remains consistent with other on-demand therapies for specialized conditions. Revenue growth hinges heavily on improving access and expanding the patient base.
Key Takeaways
- NDC 72578-0063 (Vyleesi) has modest sales with limited competition.
- Price per dose is roughly $850, with potential for slight upward adjustments.
- Market growth prospects depend on insurance reimbursement and physician awareness.
- Significant risks include emerging competitors and reimbursement policies.
- Long-term revenue could reach double current levels with increased coverage and market acceptance.
FAQs
1. How does Vyleesi compare as a treatment option for HSDD?
It offers a targeted, on-demand pharmacological approach. Its main advantage is the rapid onset of action, directly addressing patient preference for flexible use.
2. What are the main barriers to wider adoption?
Limited insurance coverage, high out-of-pocket costs, and low awareness among healthcare providers restrict broader use.
3. How likely is Vyleesi to face generic competition?
Given its recent FDA approval and patent protections, generic entry is unlikely in the next 5-7 years.
4. How might future regulatory changes impact pricing and market size?
Broader approvals or expanded indications could increase sales. Conversely, tighter reimbursement criteria may reduce patient access, suppressing revenue.
5. Are there any pending developments that could influence the market?
Potential new formulations, combination therapies, or guidelines promoting HSDD treatment could impact sales dynamics.
References
- IQVIA sales data, 2022
- FDA approval documentation for Vyleesi (2019)
- Market analysis reports on female sexual health therapeutics
- Pricing details from publicly available drug databases
